Metacare Co Ltd

Metacare Co Ltd maintains a strong liquidity position, with a current ratio of 14.43, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount to KRW 36,980,386,020, which is a substantial portion of its total assets of KRW 123,105,271,570. This liquidity is further supported by a free cash flow of KRW 14,474,477,690, suggesting the company generates more than enough cash to fund operations and potentially reinvest or return to shareholders.

In terms of profitability, Metacare demonstrates strong returns, with a return on equity (ROE) of 11.38% and a return on assets (ROA) of 11.05%. These figures are well above the typical thresholds for the pharmaceutical industry, indicating efficient use of equity and assets to generate profit. The company's operating income of KRW 9,446,504,380 and net income of KRW 13,606,752,270 further underscore its strong earnings performance.

Geographically and segment-wise, Metacare's revenue concentration is not explicitly detailed in the available data. However, the company operates primarily in South Korea, and its business is centered on pharmaceuticals and medical research. The lack of detailed segment or geographic breakdown suggests a relatively concentrated business model, which could expose the company to regional economic or regulatory risks.

Looking at growth, Metacare's recent financial performance shows a strong revenue base of KRW 4,886,450,250. While the outlook for the current and next fiscal years is not explicitly provided, the company's robust free cash flow and low capital expenditure of KRW -74,453,910 suggest a conservative approach to reinvestment. This may indicate a focus on maintaining profitability rather than aggressive expansion.

Risk factors for Metacare are currently assessed as low in terms of liquidity and dilution. The company has no immediate filing-based liquidity or dilution flags, and its debt-to-equity ratio is 0.0, indicating no long-term debt obligations. This suggests a strong financial position with minimal leverage. The absence of dilution risk is further supported by the fact that basic and diluted shares outstanding are equal, indicating no potential for share dilution from stock options or convertible securities.

Recent events and filings do not show any material changes or risks for Metacare. The company's financial statements and disclosures are consistent with a stable and well-managed business. There are no notable regulatory or operational risks highlighted in the available data, and the company appears to be in a strong position to continue its operations without significant disruptions.

Revenue surged 62.4% year-over-year to 32.8 billion KRW, demonstrating strong top-line growth momentum.

Operating margin of 1.93% ranks best-in-class compared to the 0.056% pharmaceutical cohort median.

Net margin of 2.78% significantly outperforms the 0.039% median for the pharmaceutical peer group.

The company maintains a zero debt-to-equity ratio, indicating a conservative capital structure with low leverage risk.

Long-term debt increased to 59.3 billion KRW, nearly doubling from the prior year's 35.6 billion KRW.

Cash conversion ratio of 0.25 falls below the 0.95 median for the pharmaceutical cohort.